From Ethical Guidance to Global Action: Navigating Post-Trial Access
Discover how evolving ethical guidance and real-world strategies are shaping effective, patient-centered Post-Trial Access in today’s global clinical trials.
Warning: Trying to access array offset on value of type null in /var/www/html/wp-content/themes/custom/acf-flexible/section-part/header_–_left_content_right_image_patient.php on line 18
Warning: Trying to access array offset on value of type null in /var/www/html/wp-content/themes/custom/acf-flexible/section-part/header_–_left_content_right_image_patient.php on line 22
Why attend?
Date: January 29th 2026 at 4:00pm CET/10:00am ET
What you will learn:
Understand the real-world access challenges that occur following clinical trial completion and how evolving ethical guidance for PTA impacts planning and decision making along the development path.
Identify core guiding principles for PTA and explore practical strategies for translating them into actionable plans, including selecting fit-for-purpose PTA mechanisms and exit planning.
Recognize common challenges in PTA planning and implement solutions to ensure seamless patient access and ethical compliance.
Head of Expanded Access Center of Excellence at Novo Nordisk
With 15+ years in the pharmaceutical industry, Olga currently drives Expanded Access and Post-Trial Access at Novo Nordisk, addressing the needs of the company’s diverse Rare Disease portfolio. In this role, she oversees both the strategic design and operational execution of the initiatives.
Stephanie Ferket
Director, Expanded Access Strategy and Customer Success at myTomorrows
Previously Alexion, AstraZeneca Rare Disease. Stephanie now supports biopharma companies in transforming their approach and infrastructure to drive strategic, ethical and sustainable medicines access.
John Massarelli (Moderator)
Pre-Approval Access Specialist at myTomorrows
John Massarelli is a Pre-approval Access Specialist at myTomorrows, where he focuses on the ethical and regulatory aspects of patient access to investigational drugs through clinical trials or expanded access programs.
